These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22209988)

  • 21. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
    Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
    Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
    Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
    Brazzelli V; Muzio F; Manna G; Moggio E; Vassallo C; Orlandi E; Fiandrino G; Lucioni M; Borroni G
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):2-5. PubMed ID: 22211996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 28. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
    Kitiyakara C; Atichartakarn V
    Nephrol Dial Transplant; 2002 Apr; 17(4):685-7. PubMed ID: 11917072
    [No Abstract]   [Full Text] [Related]  

  • 29. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
    Mabed M; Elhefni AM; Damnhouri G
    Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
    [No Abstract]   [Full Text] [Related]  

  • 30. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 31. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
    Raanani P; Goldman JM; Ben-Bassat I
    J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
    [No Abstract]   [Full Text] [Related]  

  • 32. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
    Lokeshwar N; Kumar L; Kumari M
    Leuk Lymphoma; 2005 May; 46(5):781-4. PubMed ID: 16019519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib-induced Stevens-Johnsons syndrome.
    Jha P; Himanshu D; Jain N; Singh AK
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Rare Case of Melanosis of the Hard Palate Mucosa in a Patient with Chronic Myeloid Leukemia.
    Romeo U; Palaia G; Fantozzi PJ; Tenore G; Bosco D
    Case Rep Dent; 2015; 2015():817094. PubMed ID: 26451262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
    Liu NS; O'Brien S
    Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
    Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
    Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STI571 as a targeted therapy for CML.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.